Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China [Phase 1, Phase 2]
Allist Pharmaceuticals is conducting a Phase 1/2 clinical trial of JAB-21822 in adults with advanced KRAS p.G12C-mutant solid tumors in Chin…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer [Phase 1, Phase 2]
A clinical trial update describing a Phase 1/2 study of the combination of amivantamab and cetrelimab in participants with metastatic non-sm…
-
CLINICAL_TRIALS withdrawal · 2026-03-13Clinical Trial Update: Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC [Phase 1, Phase 2]
A Phase 1/2 trial evaluating Vudalimab or pembrolizumab with chemotherapy as first-line treatment for advanced nonsquamous non-small cell lu…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²)
This document reports a completed clinical trial update for a cohort of non-small cell lung cancer patients with the CB(NPC)² mutation, spon…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations [Phase 3]
Phase 3 trial comparing bevacizumab plus erlotinib versus erlotinib alone in non-small cell lung cancer with activating EGFR mutations has c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) [Phase 2]
Phase 2 study at Virginia Commonwealth University evaluating reduced-dose chemotherapy plus anti-PD-1 therapy as first-line treatment for ol…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) [Phase 1]
Phase 1 clinical trial evaluating ascorbate in combination with durvalumab for non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. [Phase 1]
Phase 1 clinical trial evaluating PF-07985045 alone or with other anti-cancer therapies in adults with advanced solid tumors bearing gene al…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens [Phase 4]
This entry describes a Phase 4 clinical trial evaluating Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese patients with EGFR-…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 3]
A Phase 3 trial evaluating SKB264 in combination with pembrolizumab versus pembrolizumab alone for locally advanced or metastatic Non-Small …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
This clinical trial investigates how biological, genetic, and constitutional factors, plus non-invasive monitoring, can help assess individu…
-
CLINICAL_TRIALS other · 2026-03-13Clinical Trial Update: Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations [Phase 1]
Phase 1 clinical trial update for furmonertinib in advanced or metastatic non-small cell lung cancer with activating or uncommon EGFR/HER2 m…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer [Phase 2]
A Phase 2 trial is investigating the combination of SX-682 with atezolizumab for advanced, metastatic, or recurrent non-small cell lung canc…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is testing dual-target CAR-NK cell therapy directed against MSLN, EGFR, or HER2 in patients with advanced n…
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
A clinical trial update exploring the mechanism behind enhanced efficacy of Ivonescimab when used in neoadjuvant therapy for non-small cell …
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) [Phase 1, Phase 2]
PMV Pharmaceuticals is evaluating PC14586 in a Phase 1/2 trial for advanced solid tumors harboring the TP53 Y220C mutation. The study is cur…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC [Phase 2]
A Phase 2 trial is evaluating anti-PD-1 re-challenge after immune priming with ipilimumab and radiotherapy in advanced non-small cell lung c…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors [Phase 1]
A Phase 1 study evaluating Zanzalintinib in combination with immuno-oncology agents in patients with various solid tumors; recruitment is on…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors [Phase 1, Phase 2]
A Mayo Clinic-sponsored phase 1/2 trial evaluating a personalized neoantigen peptide-based vaccine in combination with pembrolizumab for adv…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 trial evaluating ILKN421H plus pembrolizumab for locally advanced or metastatic non-small cell lung cancer is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) [Phase 3]
The Phase 3 trial RASolve 301 evaluating daraxonrasib (RMC-6236) for RAS-mutated non-small cell lung cancer is currently recruiting. No resu…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease [Phase 2]
This update notes a Phase 2 trial evaluating HER3-DXd in metastatic breast cancer and advanced non-small cell lung cancer (including brain m…
-
CLINICAL_TRIALS other · 2026-03-12Clinical Trial Update: Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer [Phase 1]
Phase 1 clinical trial evaluating a personalized neo-antigen peptide vaccine for advanced cancers (metastatic breast cancer, melanoma, and n…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT [NA]
A multicenter randomized trial compares anesthesia approaches in suspected early-stage non-small cell lung cancer (clinical stage T1); the s…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This clinical trial update describes the use of a live tumor diagnostic platform to evaluate immune checkpoint inhibitor responses across mu…